Boston Partners’s Verastem VSTM Stock Holding History

Boston Partners’s Portfolio VSTM Stock Details VSTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,361	Closed	-$126K	–	765
2022 Q3	$126K	Buy	12,361 +4,079	+49%	+$56.9K	﹤0.01%	692
2022 Q2	$115K	Buy	+8,282	New	+$132K	﹤0.01%	687

Other funds holding VSTM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Partners's VSTM Position: Q4 2022 in Review

Boston Partners sold out of Verastem (VSTM) in Q4 2022, closing a stake of 12,361 shares — an estimated $126K sold.

Boston Partners first reported a position in VSTM in Q2 2022 and held it in 2 quarters. The position peaked at $126K in Q3 2022. 89 funds tracked by Wall St. Rank hold VSTM as of Q4 2022.

Boston Partners reported no remaining Verastem position as of Q4 2022 after selling out during the quarter.
Boston Partners sold 12,361 Verastem shares in Q4 2022, an estimated $126K.
Boston Partners first reported a position in Verastem in Q2 2022 and held it in 2 quarters.
Boston Partners's Verastem position peaked at $126K in Q3 2022.
89 funds tracked by Wall St. Rank held Verastem as of Q4 2022.

Based on Boston Partners's 13F filing for Q4 2022, filed 8 Feb 2023.